Ventana Medical Systems, Inc.05/17/2013
Ventana Medical Systems Introduction
Through innovative solutions for H&E, immunohistochemistry (IHC) and in situ hybridization (ISH), special stains, advanced workflow and digital pathology, Ventana empowers anatomic pathologists and laboratory professionals to increase testing efficiency. Our intuitive, integrated slide staining and workflow management platforms optimize laboratory operations to minimize errors, support diagnosis, and inform treatment decisions for anatomic pathology professional
Update from ASU Biodesign's Dr. Raymond DuBois
Dr. Ray DuBois, M.D., Ph.D. Dr. DuBois is a world-renowned physician-scientist who has devoted his career to understanding the linkages between inflammation and cancer, particularly colon cancer. He assumed his new role as Executive Director of the Biodesign Institute in December of 2012, coming by way of Houston as provost of the prestigious M.D. Anderson Cancer Center.
Raymond L. Woosley, MD, PhD - 2012 AZBio Pioneer
Raymond L. Woosley earned a Ph.D. in Pharmacology from the University of Louisville and an M.D. from the University of Miami. He began his career as the first scientist in the US operations for Glaxo, now known as GlaxoSmithKline. Dr. Woosley specialized in Internal Medicine and Clinical Pharmacology at Vanderbilt University where he rose to the rank of Professor of Medicine. At Georgetown University he served as Chairman of the Department of Pharmacology and in 2000 was appointed Associate Dean for Clinical Research. In 2001 he became Vice President for Health Sciences at the University of Arizona and Dean of the College of Medicine. In January of 2005 he assumed the position of President of The Critical Path Institute (C-Path), a non-profit corporation formed by the Food and Drug Administration, SRI, International and the University of Arizona to accelerate the development of safe innovative medicines. Since 1999, he has directed one of seven federally-funded (Agency for Healthcare Research and Quality) Centers for Education and Research on Therapeutics (CERT).Under Dr. Woosley’s leadership, C-Path (the Critical Path Institute) orchestrated the acceleration of medical product development through a unique collaborative process among industry, academia, and the FDA. Our collaborations among 6 global consortia, 1000+scientists, and 41 companies has already produced these notable successes:
- First preclinical safety biomarkers (7) qualified by the FDA, EMA, and PMDA (the Japanese counterpart)
- First CDISC (Clinical Data Interchange Standards Consortium) therapeutic area data standard
- First and largest open database of CDISC aggregated clinical trial data for Alzheimer’s disease (6,100 patients and 22 clinical trials) Read more
- First drug-disease trial model & clinical trial simulation tool submitted and under review by the FDA
- First imaging biomarker for trial enrichment qualified by the EMA
Dr. Woosley’s research has investigated the basic and clinical pharmacology of drugs for the treatment of arrhythmias and the cardiac toxicity of drugs, and has been published in over 260 publications. His research discovered the mechanism of the toxicity of the antihistamine Seldane®. He is the recipient of the Rawls-Palmer Award from the American Society of Clinical Pharmacology and Therapeutics for his contributions to medicine and the FDA Commissioner’s Special Citation for his work to advise the agency on the toxicity of dietary supplements containing ephedra. Dr. Woosley is a Past-President of the Association for Medical School Pharmacology and the American Society for Clinical Pharmacology and Therapeutics. He has served on numerous boards including the US Pharmacopeia. He is a member of the Biodesign Institute at Arizona State University. As a member of the University of Arizona’s Sarver Heart Center and Bio5 Institute, he conducts research on the prevention of adverse drug interactions.
SynCardia Systems, Inc.06/13/2013
Getting to the Destination: Dr. Marvin Slepian, SynCardia
Marvin J. Slepian, M.D.Co-Founder, Chief Scientific and Medical Officer,
Science Advisory Board Chairman
Honoring U.S. Senator Jon Kyl
As Arizona celebrated its Centennial, AZBio honored Arizona Senator Jon Kyl for his dedication and service to both our industry and the people of our state with the 2012 AZBio Centennial Award.Senator Kyl is serving his third and final term in the U.S. Senate after previously serving for eight years in the U.S. House of Representatives. He was elected unanimously by his colleagues in 2008 to serve as Republican Whip, the second-highest position in Senate Republican leadership.
Enjoy Senator Kyl's remarks about Arizona's Bioindustry and the introduction by Fritz Bittenbender of the Biotechnology Industry Association (BIO)
Arizona Pioneer Thomas M. Grogan, MD
Thomas M. Grogan, M.D., Founder of Ventana and SVP, Medical Affairs of Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, receives the AZBio Pioneer Award for Lifetime Achievement at the 2013 AZBio Awards on October 10, 2013.
Dr. Grogan was a pathologist and professor at the University of Arizona when in the mid 1980’s he and a small team set out to challenge the limitations of the then current standards and processes for cancer pathology. What was to become the company’s first digital pathology instrument evolved from Grogan’s notes on a yellow pad into the BenchMark IHC/ISH staining platforms. Under Grogan’s leadership, Ventana was founded in 1987, went public in 1996, and was acquired by Roche for $3.4 billion in 2008. Over the last 25 years, Ventana has grown to become a global leader in developing and manufacturing tissue-based diagnostic instruments and tests focused on the detection of cancer. Ventana employees continue to pursue the same deeply rooted mission of innovating diagnostic testing and enabling personalized healthcare to improve the lives of all patients afflicted with cancer worldwide.
Dr. Grogan has made it his personal mission to make life better for the millions of patients who battle cancer each day. His passion and dedication are infectious and has spread across the company that he and his team built. Through their efforts they have revolutionized the field of cancer diagnostics and are pioneering new roads in the field of personalized healthcare.”
Leadership Conversation with Nobel Laureate Leland Hartwell, PhD
How will we create sustainable health? What innovations can make a difference? What is the role of education? Lee Hartwell, PhD, is the Virginia G. Piper Chair in Personalized Medicine at the Center for Sustainable Health, Biodesign Institute, Arizona State University. At the Center his work focuses on creating effective learning environments. The first is a course required for all K-8 teachers, Sustainability Science for Teachers and the second is Project Honey Bee, an interdisciplinary research project to validate wearable devices for ambulatory patient management. He also oversees a project to develop biomarkers for the clinical management of many diseases at the Chang Gung Memorial Hospital and University in Taipei, Taiwan. Dr. Hartwell was awarded the 2001 Nobel Prize in Physiology or Medicine for identifying genes that control cell division in yeast.